Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) for COVID-19 - living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
Asano NCT04568031		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	placebo	COVID-19 prophylaxis (excluding children)	NA	-/-	inconclusive
AstraZeneca phase 3 US (D8110C00001) NCT04516746		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	placebo	COVID-19 prophylaxis (excluding children)	NA	21583/10796	safety concern	suggested 76 % decrease in symptomatic Covid-19 statistically significant 62 % increase in adverse events statistically significant vaccine efficacy of 78.9% in preventing symptomatic COVID-19 and 100% efficacy in preventing severe or critical disease and hospitalization. In participants 65 years and older, who comprised 20% of the trial population, vaccine efficacy against symptomatic COVID-19 was 79.9%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis